Background {#s1}
==========

Severe 5,10-Methylenetetrahydrofolate reductase (MTHFR; OMIM 236250) deficiency is a rare inborn error of metabolism and inherited in an autosomal recessive fashion. It is a very common disorder of folate metabolism and is clinically characterized with low plasma methionine level, high homocysteine level, homocystinuria, and hyperhomocysteinemia ([@B1], [@B2]).

*MTHFR* gene is responsible for the assembly of MTHFR enzyme, which plays a very important role in the catalysis of 5,10-methyltetrahydrofolate (THF) to 5-methyltetrahydrofolate (an NADPH-dependent irreversible reduction) to obtain methionine from homocysteine ([Supplementary Figure 1](#SM2){ref-type="supplementary-material"}). Methyl THF is the most common form of folate in tissues and the plasma and serves as the methyl group donor in the methyl THF-homocysteine S-methyltransferase reaction involving remethylation of homocysteine to methionine ([@B3]).

The deficiency of MTHFR enzyme causes an increase in the concentration of homocysteine and methionine, resulting in severe neurological phenotypes. Patients having neonatal onset (i.e., early onset \<1-year-old) MTHFR deficiency are mostly associated with feeding problems, neurological phenotype, microcephaly, seizures, and communicating hydrocephalus, while the late onset is characterized with delayed developmental milestones, cognitive impairment and/or gait abnormalities, stroke, apnoea, paresthesia, psychiatric disturbances, and neurological deterioration, which lead to coma and even death ([@B4], [@B5]).

In the present study, we performed direct whole exome sequencing (WES) to ascertain the genetic cause of severe MTHFR deficiency in the single affected individual (proband). As a result, we identified a homozygous non-sense mutation in *MTHFR* gene located on chromosome 1p36.22.

Case Presentation {#s2}
=================

Clinical Examination
--------------------

The proband (III-7) genetically and clinically analyzed in the present study belongs to a non-consanguineous Egyptian family ([Figure 1A](#F1){ref-type="fig"}). The parents had total seven children, three had deceased (III-1, III-2, and III-3) and showed (i.e., early onset \<1 year old) similar phenotypes as the proband, healthy twin daughters (III-4 and III-5), one miscarriage (III-6), and the proband (III-7) (early onset \<1 year). The deceased children age were: III-1:40 days, III-2: 2 months, III-3: 45 days; and all the deceased children became lethargic, hypoactive with poor suckling, with associated prolonged sleepiness. These were referred to the neonatal intensive care unit (NICU) as quarry neonatal sepsis. Computed tomography (CT) scan revealed subarachnoid hemorrhage and the patients died of apnoea, disseminated intravascular coagulation (DIC), and cardiorespiratory arrest.

![**(A)** Pedigree of the family segregating severe MTHFR deficiency. Pedigree clearly depicts an autosomal recessive mode of inheritance. Circles and squares represent females and males, respectively. Clear symbols represent normal, while filled symbols represent affected individuals. Slashes represents deceased individuals and triangle represents spontaneous abortion (SAB). The individual numbers labeled with asterisks were subjected to WES and the red arrow indicates the proband. **(B)** Pictures of the affected individual exhibiting microcephalic features at 1 month of age. **(C)** Brain MRI showing axial, coronal, and both T2 weighted images. These images revealed bilateral abnormal and symmetrical high signal intensity along the bilateral frontal horn in white matter, and the superior part of the periventricular deep white matter as well as within the subcortical basal temporal lobe white matter. The images also showed severely dilated ventricles and loss of white matter in cerebral hemispheres with prominent extra-axial CSF spaces. **(D)** A recent photograph of the proband (III-7) showing severe MTHFR deficiency.](fneur-10-00411-g0001){#F1}

First Clinical Evaluation
-------------------------

During the first clinical investigation, the proband (female; III-7) was 1-month-old with features such as non-obstructive hydrocephalus, recurrent apnea, microcephaly, and white matter abnormality ([Figure 1B](#F1){ref-type="fig"}). The proband showed delayed growth during the last month of gestation. At birth, the head circumference was 31.5 cm, and the birth weight was 2,980 grams ([Figure 1B](#F1){ref-type="fig"}). After 14 days, the proband developed apnea attacks and bradypnea and showed difficulties with swallowing. Ophthalmological examination demonstrated bilateral optic nerve hypoplasia, left retinal multiple hemorrhages, and normal anterior segment. The laboratory screening results revealed low white blood cell count, low platelet count, and high number of lymphocytes. Following multiple episodes of apnea, multi-sequential and multiplanar magnetic resonance imaging (MRI) was performed. The MRI findings showed bilateral abnormal almost symmetrical T2. High signal intensity was observed in the white matter along the bilateral horn deep in the white matter, suggestive of white matter disease ([Figure 1C](#F1){ref-type="fig"}). No chest infection, deafness, or cardiovascular anomaly was noted. The proband had a total blood homocysteine level of 163 nmol/mL (normal, 3.7--12.5 nmol/mL) and the plasma methionine range of \< 5 (10--39 μmol/L). The proband was on regular medication such as betaine (100 mg·kg^−1^·day^−1^), methionine (50 mg·kg^−1^·day^−1^), vitamin B12 (5 mg PO 1/day), and L-5-MTHF (15 mg PO 1/day).

Follow-Up Examination
---------------------

Follow-up examination after 10 months revealed that the proband could support her head but could not sit without support and may easily roll over ([Figure 1D](#F1){ref-type="fig"}). Ophthalmic examination revealed optic atrophy, retinal hemorrhage, and the affected individual was unable to fix eyes nor follow. No hearing abnormality was observed. The proband was able to make sounds at the age of 4--5 months. Physical examination revealed a height of 79 cm (\>95th percentile), weight of 10.7 kg (\>95th percentile), and head circumference of 48 cm (\>95th percentile). The total blood homocysteine level was 68 nmol/mL (normal, 3.7--12.5 nmol/mL), while the plasma methionine level was 54 μmol/L (normal, 10--39 μmol/L).

Materials and Methods {#s3}
=====================

Study Approval and Sample Collection
------------------------------------

The present study was approved by the Institutional Review Board (KAIMRC) and followed Helsinki protocols. Written informed consent was obtained from the parents of the participant for the research study, presentation of photographs/radiographs, and publication of this case report.

DNA Extraction
--------------

DNA was extracted from peripheral blood samples using QIAamp DNA Micro kit (Hilden, Germany) and quantified using NanoDrop™ spectrophotometer using standard procedures.

WES
---

WES was commercially performed (Centogene, Rostock, Germany) for five family members, including the single affected individual (proband: III-7), both parents (II-3 and II-4), and twin sisters (III-4 and III-5) using Illumina platform (Illumina, Inc., San Diego, CA, USA; [Figure 1A](#F1){ref-type="fig"}). RNA capture baits against approximately 60 Mb of the human exome (targeting \>99% of regions in the consensus coding sequence, RefSeq, and Gencode databases) were used to enrich the regions of interest from the fragmented genomic DNA with the SureSelect Human All Exon V6 kit (Agilent Technologies, Santa Clara, CA, USA). The generated library was sequenced to obtain an average coverage depth of about 100X. In general, about 97% of the targeted bases are covered in more than 10X. Data analysis and interpretation were performed by Centogene using an end-to-end in-house bioinformatic pipeline with applications including base calling and alignment of reads to the GRCh37/hg19 (GRCh37; <http://genome.ucsc.edu/>) genome assembly.

Filtering of the Disease-Causing Variants
-----------------------------------------

Primary filtering out of low-quality reads and probable artifacts and the subsequent annotation of variants were performed using standard methods. As the pedigree depicted autosomal recessive inheritance, homozygous and compound heterozygous variants were preferred but heterozygous variants were not ignored.

The variants were filtered and validated using standard methods ([@B6]) and screened in different databases such as dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP/>), 1000 genomes Project (<http://www.internationalgenome.org/>), ExAC (<http://exac.broadinstitute.org/>), and gnomAD (<http://gnomad.broadinstitute.org/>). Screening for the disease-causing variants (homozygous and compound heterozygous) led to the identification of a novel homozygous non-sense mutation (c.154C\>T; p.Arg52^\*^) in the exon 1 of *MTHFR* gene (NM_005957.4). Both the parents were heterozygous for the identified variant. The identified variant was absent in different available databases (dbSNP, 1000 genomes, ExAC, and gnomAD) and several in-house exomes (control).

*In silico* Analysis
--------------------

Pathogenicity of the identified variant was evaluated with different online mutation prediction tools such as MutationTaster (mutationtaster.org), DNN (<https://cbcl.ics.uci.edu/public_data/DANN/>), FATHMM (fathmm.biocompute.org.uk), LRT (genetics.wustl.edu/jflab/lrt_query.html), VarSome (<https://varsome.com/>), CADD---Combined Annotation Dependent Depletion (<https://cadd.gs.washington.edu/>), and MutationAssessor (mutationassessor.org).

The identified variant (c.154C\>T) was also subjected to Sanger sequencing with all the available members of the family using standard methods (Centogene, Germany), and the variant was shown to perfectly segregate with the disease phenotype.

Discussion and Conclusions {#s4}
==========================

MTHFR (EC 1.5.1.20) is a key enzyme of the folate cycle involved in the catalysis of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for the remethylation of homocysteine to methionine. Methionine is subsequently metabolized to form S-adenosylmethionine. Thus, any disturbance in the pathway, either through the supply of cobalamin/folate or MTHFR deficiency, may cause accumulation of homocysteine, leading to altered patterns of methylation \[([@B7]--[@B9]); [Supplementary Figure 1](#SM2){ref-type="supplementary-material"}\].

In the present study, we investigated a single affected individual (III-7) with MTHFR deficiency demonstrating severe features such as microcephaly, delayed growth, ophthalmic issues, non-obstructive hydrocephalus, elevated blood homocysteine level, and elevated plasma methionine levels. Features reported in the proband were similar to the previously reported cases ([@B9]--[@B13]). The affected individual had an early onset (\<1 year) of the disease. It has been previously observed that the patients with early onset exhibit lesser residual enzyme activity than those with late onset (\>1 year) ([@B12]). Residual enzyme activity was not tested in the present study. We performed WES for all the available members of the family ([Figure 1A](#F1){ref-type="fig"}) and identified a homozygous non-sense mutation (c.154C\>T; p.Arg52^\*^) in *MTHFR* gene. The non-sense mutation (p.Arg52^\*^) was located within the catalytic domain and most likely resulted in the complete loss of function of the MTHFR protein, either through non-sense-mediated mRNA decay or via the production of a truncated MTHFR protein.

*MTHFR* gene is located on chromosome 1p36.22, exhibits 11 exons, and encodes a 656 amino acid protein (NP_005948.3) ([Figure 2A](#F2){ref-type="fig"}). MTHFR protein exists as a homodimer comprising two N-terminal catalytic domains with binding sites for NADPH, methylene-THF, and cofactor FAD-linked to the regulatory domain (C-terminus) ([Figure 2B](#F2){ref-type="fig"}). The mutation (p.Arg52^\*^) identified herein is highly conserved across different species ([Figure 2C](#F2){ref-type="fig"}). The exact association between the position of mutation and clinical phenotypes is yet unknown, as a biallelic loss-of-function mutation in any part of the protein results in extreme enzyme deficiency. This phenomenon highlights the importance of the complete peptide for proper enzyme activity ([@B14]).

![**(A)** *MTHFR* gene structure highlighting the already reported splice site and small deletion mutations. The variant identified in the present study is represented within a box. **(B)** Schematic representation of MTHFR protein and different domains. Missense and non-sense mutations are shown along each domain. The mutation identified in the present study is represented within a box. **(C)** Partial amino acid sequence of MTHFR protein showing conservation of Arg52 amino acid residue across different species.](fneur-10-00411-g0002){#F2}

As per our knowledge, 132 mutations have been reported in *MTHFR* gene that may cause several disorders such as homocystinuria, anencephaly, tetralogy of Fallot with cleft lip/palate, MTHFR deficiency, acute aortic dissection, reduced enzyme activity, association with preeclampsia, increased erythrocyte folate, respiratory failure and hypotonia, coronary heart disease, Ehlers-Danlos syndrome IV, and Facial palsy ([@B11], [@B13], [@B15]--[@B18]). Clinical comparison of patients with non-sense mutations in *MTHFR* gene has been compiled in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}. Only 84 different mutations have been described in the literature that cause severe MTHFR deficiency, including 52 missense mutations, 12 splice acceptor/donor site, 8 non-sense mutations, 7 small deletions, 2 small indels, 2 start loss, and 1 gross insertion ([Table 1](#T1){ref-type="table"}). The majority of the mutations causing severe MTHFR deficiency are reported in the catalytic domain ([Figure 2B](#F2){ref-type="fig"}).

###### 

Mutations reported in the *MTHFR* gene causing a severe 5-10-MTHFR deficiency.

       **Disorder**       **Amino acid change**   **Nucleotide change**   **Mutation type**       **Exon/Intron**   **Domain**
  ---- ------------------ ----------------------- ----------------------- ----------------------- ----------------- -------------
  1    MTHFR deficiency   Arg6\*                  c.16A\>T                Non-sense               Exon 1            Serine rich
  2    MTHFR deficiency   Arg46Gln                c.137G\>A               Missense                Exon 1            Catalytic
  3    MTHFR deficiency   Arg46Trp                c.136C\>T               Missense                Exon 1            Catalytic
  4    MTHFR deficiency   Trp59Cys                c.177G\>T               Missense                Exon 1            Catalytic
  5    MTHFR deficiency   Trp59Ser                c.176G\>C               Missense                Exon 1            Catalytic
  6    MTHFR deficiency   Pro66Leu                c.197C\>T               Missense                Exon 1            Catalytic
  7    MTHFR deficiency   Arg68Gly                c.202C\>G               Missense                Exon 1            Catalytic
  8    MTHFR deficiency   Ser78\*                 c.233C\>G               Non-sense               Exon 1            Catalytic
  9    MTHFR deficiency   Arg82Trp                c.244C\>T               Missense                Exon 2            Catalytic
  10   MTHFR deficiency   Ala113Thr               c.337G\>A               Missense                Exon 2            Catalytic
  11   MTHFR deficiency   Ala116Thr               c.346G\>A               Missense                Exon 2            Catalytic
  12   MTHFR deficiency   His127Tyr               c.379C\>T               Missense                Exon 2            Catalytic
  13   MTHFR deficiency   Thr129Asn               c.386C\>A               Missense                Exon 2            Catalytic
  14   MTHFR deficiency   Thr139Met               c.416C\>T               Missense                Exon 2            Catalytic
  15   MTHFR deficiency   Gln147Pro               c.440A\>C               Missense                Exon 2            Catalytic
  16   MTHFR deficiency   Ala175Thr               c.523G\>A               Missense                Exon 3            Catalytic
  17   MTHFR deficiency   His181Asp               c.541C\>G               Missense                Exon3             Catalytic
  18   MTHFR deficiency   Arg183Gln               c.548G\>A               Missense                Exon 3            Catalytic
  19   MTHFR deficiency   Cys193Tyr               c.578G\>A               Missense                Exon 3            Catalytic
  20   MTHFR deficiency   Ala195Val               c.584C\>T               Missense                Exon 3            Catalytic
  21   MTHFR deficiency   Gly196Asp               c.587G\>A               Missense                Exon 3            Catalytic
  22   MTHFR deficiency   Pro202Thr               c.604C\>A               Missense                Exon 4            Catalytic
  23   MTHFR deficiency   Ile225Leu               c.673A\>C               Missense                Exon 4            Catalytic
  24   MTHFR deficiency   Ala233Gly               c.698C\>G               Missense                Exon 4            Catalytic
  25   MTHFR deficiency   Val253Phe               c.757G\>T               Missense                Exon 4            Catalytic
  26   MTHFR deficiency   Pro254Ser               c.760C\>T               Missense                Exon 4            Catalytic
  27   MTHFR deficiency   Gly255Val               c.764G\>T               Missense                Exon 4            Catalytic
  28   MTHFR deficiency   Ile256Asn               c.767T\>A               Missense                Exon 4            Catalytic
  29   MTHFR deficiency   Phe257Val               c.769T\>G               Missense                Exon 4            Catalytic
  30   MTHFR deficiency   Asn324Ser               c.971A\>G               Missense                Exon 5            Catalytic
  31   MTHFR deficiency   Leu333Pro               c.998T\>C               Missense                Exon 5            Catalytic
  32   MTHFR deficiency   Arg335His               c.1004G\>A              Missense                Exon 5            Catalytic
  33   MTHFR deficiency   Trp339Gly               c.1015T\>G              Missense                Exon 5            Catalytic
  34   MTHFR deficiency   Arg345Cys               c.1033C\>T              Missense                Exon 5            Catalytic
  35   MTHFR deficiency   Pro348Ser               c.1042C\>T              Missense                Exon 6            Regulatory
  36   MTHFR deficiency   His354Tyr               c.1060C\>T              Missense                Exon 6            Regulatory
  37   MTHFR deficiency   Arg357His               c.1070G\>A              Missense                Exon 6            Regulatory
  38   MTHFR deficiency   Arg358\*                c.1072C\>T              Non-sense               Exon 6            Regulatory
  39   MTHFR deficiency   Arg363His               c.1088G\>A              Missense                Exon 6            Regulatory
  40   MTHFR deficiency   Lys372Glu               c.1114A\>G              Missense                Exon 6            Regulatory
  41   MTHFR deficiency   Tyr374\*                c.1122C\>G              Non-sense               Exon 6            Regulatory
  42   MTHFR deficiency   Arg377His               c.1130G\>A              Missense                Exon 6            Regulatory
  43   MTHFR deficiency   Trp381Arg               c.1141T\>C              Missense                Exon 6            Regulatory
  44   MTHFR deficiency   Gly387Asp               c.1160G\>A              Missense                Exon 6            Regulatory
  45   MTHFR deficiency   Trp421Ser               c.1262G\>C              Missense                Exon 7            Regulatory
  46   MTHFR deficiency   Ser440Leu               c.1319C\>T              Missense                Exon 7            Regulatory
  47   MTHFR deficiency   Glu470\*                c.1408G\>T              Non-sense               Exon 8            Regulatory
  48   MTHFR deficiency   Tyr506Asp               c.1516T\>G              Missense                Exon 8            Regulatory
  49   MTHFR deficiency   Tyr512Cys               c.1535A\>G              Missense                Exon 9            Regulatory
  50   MTHFR deficiency   Arg535Gln               c.1604G\>A              Missense                Exon 9            Regulatory
  51   MTHFR deficiency   Arg535Trp               c.1603C\>T              Missense                Exon 9            Regulatory
  52   MTHFR deficiency   Val536Phe               c.1606G\>T              Missense                Exon 9            Regulatory
  53   MTHFR deficiency   Trp561\*                c.1683G\>A              Non-sense               Exon 10           Regulatory
  54   MTHFR deficiency   Arg567\*                c.1699C\>T              Non-sense               Exon 10           Regulatory
  55   MTHFR deficiency   Pro572Leu               c.1715C\>T              Missense                Exon 10           Regulatory
  56   MTHFR deficiency   Val575Gly               c.1724T\>G              Missense                Exon 10           Regulatory
  57   MTHFR deficiency   Met581Ile               c.1743G\>A              Missense                Exon 10           Regulatory
  58   MTHFR deficiency   Lys584\*                c.1750A\>T              Non-sense               Exon 10           Regulatory
  59   MTHFR deficiency   Leu598Pro               c.1793T\>C              Missense                Exon 11           Regulatory
  60   MTHFR deficiency   Leu628Pro               c.1883T\>C              Missense                Exon 11           Regulatory
  61   MTHFR deficiency   \*657Arg                c.1969T\>C              Stop loss               Exon 11           Regulatory
  62   MTHFR deficiency   \*657Ser                c.1970G\>C              Stop loss               Exon 11           Regulatory
  63   MTHFR deficiency   --                      c.236+1G\>A             Splice                  Intron 2          Catalytic
  64   MTHFR deficiency   --                      c.474A\>T               Splice                  Exon 2            Catalytic
  65   MTHFR deficiency   --                      c.781-2A\>G             Splice                  Intron 5          Catalytic
  66   MTHFR deficiency   --                      c.781-1G\>A             Splice                  Intron 5          Catalytic
  67   MTHFR deficiency   --                      c.780+1G\>T             Splice                  Intron 5          Catalytic
  68   MTHFR deficiency   --                      c.1166G\>A              Splice                  Exon 6            Catalytic
  69   MTHFR deficiency   --                      c.1166+1G\>A            Splice                  Intron 7          Catalytic
  70   MTHFR deficiency   --                      c.1347+1G\>A            Splice                  Intron 8          Regulatory
  71   MTHFR deficiency   --                      c.1530+2T\>C            Splice                  Intron 9          Regulatory
  72   MTHFR deficiency   --                      c.1632+2T\>G            Splice                  Intron 10         Regulatory
  73   MTHFR deficiency   --                      c.1753-18G\>A           Splice                  Intron 10         Regulatory
  74   MTHFR deficiency   --                      c.1752+1G\>T            Splice                  Intron 11         Regulatory
  75   MTHFR deficiency   --                      c.643_645delAAG         Small deletions         Exon 4            
  76   MTHFR deficiency   --                      c.-40\_-41delTC         Small deletions 5′UTR   Intron 1          Serine rich
  77   MTHFR deficiency   --                      c.662delG               Small deletions         Exon 4            Catalytic
  78   MTHFR deficiency   --                      c.677_679delTCA         Small deletions         Exon 4            Catalytic
  79   MTHFR deficiency   --                      c.1167-2delA            Small deletions         Exon 7            Regulatory
  80   MTHFR deficiency   --                      c.1593delG              Small deletions         Exon 9            Regulatory
  81   MTHFR deficiency   --                      c.1539dupA              Small deletions         Exon 9            Regulatory
  82   MTHFR deficiency   --                      c.446_447delGCinsTT     Small indels            Exon 2            Catalytic
  83   MTHFR deficiency   --                      c.1797_1808delins12     Small indels            Exon 11           Regulatory
  84   MTHFR deficiency   Leu89_Pro101dup         c.276_314dup            Gross insertions        Exon 2            Catalytic

Furthermore, *MTHFR* knockout mice showed a decrease in methionine level, methionine/homocysteine ratio, dimethylglycine level, and lipid deposition in proximal aorta along with changes in cerebellar pathology, reduced cerebellum, reduced cerebral cortex, and developmental issues ([@B19]--[@B21]). A therapeutic strategy employing biochemical methods is important to normalize methionine level and decrease the plasma levels of homocysteine. Treatment for severe MTHFR deficiency is heterogeneous, and different combination and dosage of drugs are prescribed depending on the severity of the disorder. High doses of betaine have been suggested for patients with severe MTHFR deficiency ([@B22], [@B23]). Vitamins B6 and B12 supplementation with folic acid is also significant in the conversion of homocysteine into methionine. In the present study, the proband was prescribed a combination of betaine, methionine, vitamin B12, and L-5-MTHF that improved the overall condition, as she became more active, alert, and oriented and survived as compared to her affected siblings. At present, the proband is 14 months old, shows no apnea or seizure; hydrocephalus is not progressive and developmentally she can roll over. However, she is unable to sit, crawl, or walk and functions as a 4--5 months old infant. Folic acid dosages in combination with folate/folinic acid, hydroxocobalamin, cyanocobalamin, riboflavin, and carnitine have also been previously prescribed to some patients that could partially reduce the clinical symptoms and biochemical abnormalities ([@B5]).

In conclusion, we identified a novel biallelic non-sense mutation in a single affected individual suffering from severe MTHFR deficiency. MTHFR deficiency is potentially treatable when properly diagnosed at early stages. Clinicians should be aware of the phenotypes related to early-late onset of the disease. Timely molecular diagnosis and treatment with high dose of methyl donors is critical for the survival of these patients. Identification of the pathogenic variants of *MTHFR* gene may extend the knowledge about the spectrum of mutations and highlight the proper genotype-phenotype correlation.
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